Page 204 - 2019_06-Haematologica-web

F.I. Mulder et al.
Incidence, risk factors and clinical implica- tions of venous thromboembolism in can- cer patients treated within the context of phase I studies: The “sendo experience.” Ann Oncol. 2012;23(6):1416-1421.
10. Bezan A, Posch F, Ploner F, et al. Risk strat- ification for venous thromboembolism in patients with testicular germ cell tumors. PLoS One. 2017;12(4):1-15.
11. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097.
12. Hayden J a, Windt D a Van Der, Cartwright JL, Co P. Research and reporting methods annals of internal medicine assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280-286.
13. Sterne JAC, Harbord RM. Funnel plots in meta-analysis. Stata J. 2004;4(2):127-141.
14. den Exter PL, Hooijer J, Dekkers OM, Huisman M V. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 2011;29(17):2405-2409.
15. Font C, Carmona-Bayonas A, Beato C, et al. Clinical features and short-term out- comes of cancer patients with suspected and unsuspected pulmonary embolism: The EPIPHANY study. Eur Respir J. 2017;49(1):1600282.
16. Sahut D’Izarn M, Caumont Prim A, Planquette B, et al. Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case-control study. J Thromb Haemost. 2012; 10(10):2032-2038.
17. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 SUPPL.):419-494.
18. Debray TPA, Damen JAAG, Snell KIE, et al. A guide to systematic review and meta- analysis of prediction model performance. BMJ. 2017;356:i6460.
19. Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW. Primary pro- phylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2012;(2):CD008500.
20. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous throm- boembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023.
21. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-asso- ciated venous thromboembolism. N Engl J Med. 2018;378(7):615-624.
22. Pabinger I, van Es N, Heinze G, et al. A clin- ical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018;5(7):e289-e298.
23. Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboem- bolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291-292.
24. Pelzer U, Sinn M, Stieler J, Riess H. Primäre medikamentöse thromboembolieprophy-
laxe bei ambulanten patienten mit fort- geschrittenem pankreaskarzinom unter chemotherapie? Dtsch Med Wochenschr. 2013;138(41):2084-2088.
25. Abdel-Razeq H, Mansour A, Abdulelah H, et al. Thromboembolic events in cancer patients on active treatment with cisplatin- based chemotherapy: another look! Thromb J. 2018;16:2.
26. Ades S, Kumar S, Alam M, et al. Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic col- orectal cancer. J Thromb Haemost .2015;13(6):998-1003.
27. Austin K, Borrowman J, Blake L, Scully M, Thomas M. Retrospective cohort study of venous thromboembolism (VTE) rates in ambulatory cancer patients, and associa- tion with Khorana Score. Res Pract Thromb Haemost. 2017;11-1451.
28. Ayyappan SR, Gupta V, Diamond A, et al. Venous thromboembolic events in diffuse large B cell lymphoma patients: risk factors and outcomes. Blood. 2016; 128(22):3611.
29. Borchmann S, Hude I, Müller H, et al. thrombosis in Hodgkin lymphoma patients: incidence, time points, risk factors and impact of stage and treatment. Blood. 2016;128(22):4151.
30. Cella CA, Di Minno G, Carlomagno C, et al. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. Oncologist. 2017; 22(5):601-608.
31. Ferroni P, Riondino S, Formica V, et al. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical sig- nificance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. Int J Cancer. 2015;136(5):1234-1240.
32. Ferroni P, Martini F, Portarena I, et al. Novel high-sensitive D-Dimer determination pre- dicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. Clin Lung Cancer. 2012;13(6):482-487.
33. Fuentes HE, Oramas DM, Paz LH, Wang Y, Andrade XA, Tafur AJ. Venous throm- boembolism is an independent predictor of mortality among patients with gastric can- cer. J Gastrointest Cancer. 2017;1-7.
34. George D, Agnelli G, Fisher W, et al. Venous thromboembolism (VTE) preven- tion with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. Blood. 2011;118(21):206 LP-206.
35. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601-609.
36. Guadagni F, Riondino S, Formica V, et al. Clinical significance of glycemic parame- ters on venous thromboembolism risk pre- diction in gastrointestinal cancer. World J Gastroenterol. 2017;23(28):5187-5195.
37. Kearney JC, Rossi S, Glinert K, Henry DH. Venous thromboembolism (VTE) and sur- vival in a cancer chemotherapy outpatient clinic: a retrospective chart review valida- tion of a VTE predictive Model. Blood. 2009;114(22):2503.
38. Khorana AA, Francis CW, Kuderer NM, et al. Dalteparin thromboprophylaxis in can- cer patients at high risk for venous throm- boembolism: a randomized trial. Thromb Res. 2017;151:89-95.
39. Khorana AA, Rubens D, Francis CW. Screening high-risk cancer patients for VTE: A prospective observational study. Thromb Res. 2014;134(6):1205-1207.
40. Kim SY, Burns ZT, Henry DH. The assess- ment of thrombotic risk using a predictive model in metastatic cancer patients under- going first-line therapy. Thromb Res. 2012; 130(6):967-970.
41. Kruger S, Haas M, Burkl C, et al. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer – A retrospective cohort study. Thromb Res. 2017;157:9-15.
42. Kuderer NM, Poniewierski MS, Culakova E, et al. Predictors of venous thromboembolism and early mortality in lung cancer: results from a global prospective study (CAN- TARISK). Oncologist. 2018;23(2):247-255.
43. Kuk A, Magnowska M, Suchy W, et al. Retrospective evaluation of Thromboembolism risk in ovarian cancer patients treated with Bevacizumab. Target Oncol. 2017;12(4):495-503.
44. Kunapareddy G, Switzer B, Conces M, et al. Implementation of an Electronic medical record tool for early detection of deep vein thrombosis in the Ambulatory oncology Setting: the Cleveland Clinic Experience. Blood. 2017;130(Suppl 1):3361.
45. Lim SH, Woo SY, Kim S, Ko YH, Kim WS, Kim SJ. Cross-sectional study of patients with diffuse large B-cell lymphoma: assess- ing the effect of host status, tumor burden and inflammatory activity on venous thromboembolism. Cancer Res Treat. 2015;48(1):1-10.
46. Lubberts S, Boer H, Altena R, et al. Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemother- apy. Eur J Cancer. 2016;63:180-188.
47. Lustig D Ben, Rodriguez R, Wells PS. Implementation and validation of a risk stratification method at the Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermedi- ate-high risk for venous thrombosis. Thromb Res. 2015;136(6):109-1102.
48. Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost. 2016;14(9):1773-1778.
49. Misch M, Czabanka M, Dengler J, et al. D- dimer elevation and paresis predict throm- boembolic events during bevacizumab therapy for recurrent malignant glioma. Anticancer Res. 2013;33(5):2093-2098.
50. Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analy- sis. J Clin Oncol. 2011;29(25):3466-3473.
51. Muñoz Martín AJ, Ortega I, Font C, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018; 118(8):1056-1061.
52. Muñoz Martín AJ, García Alfonso P, Rupérez Blanco AB, et al. Incidence of venous thromboembolism (VTE) in ambu- latory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model. Clin Transl Oncol. 2014; 16(10):927-930.
53. Noble S, Robbins A, Alikhan R, Hood K, Macbeth F. Prediction of venous throm- boembolism in lung cancer patients receiv- ing chemotherapy. Int Soc Thromb Haemost. 2015;131-997.
54. Macbeth F, Noble S, Evans J, et al. Randomized phase III trial of standard ther- apy plus low molecular weight heparin in
1286
haematologica | 2019; 104(6)